Visionary Holdings (NASDAQ:GV) shares surged 35.8% after hours to $0.28 Wednesday after the Toronto-based company announced a US$20 million investment cooperation agreement with Qingdao Xihai Rongke on Tuesday for an anti-aging project in China.

Qingdao Xihai Rongke serves as both a strategic partner and an investor in the proposed anti-aging and healthcare project.

Phased Funding Structure And Profitability Target

Under the agreement, the parties will set up a project company to launch a “GV China Anti-Aging Research Center” and a chain of “GV Anti-Aging Health Management Centers,” with initial operations focused on the Shandong market.

Visionary Holdings said the $20 million will be disbursed in milestone-based installments of 30%, 40% and 30%, with an additional $10 million in a second phase contingent on development progress.

Xiyong Hou, CEO of Visionary Holdings, said the agreement establishes a "defined framework," though closing remains subject to definitive agreements and customary conditions.

The company also targets first-center profitability within one year post-investment.

GV reported a loss of $4.15 per share on revenue of $5.04 million in its fiscal year earnings report in January. Its next first-half results are due Apr. 15.

Trading Metrics, Technical Analysis

With a market capitalization of $1.14 million, Visionary Holdings has a 52-week high of $4.18 and a 52-week low of $0.18.

The Relative Strength Index (RSI) of GV stands at 19.95.

Over the past 12 months, the small-cap stock of the technology-driven multinational focused on biotechnology and healthcare has gained 78.51%.

Price Action: According to Benzinga Pro data, GV closed the regular session at $0.20, down 23.22%.

The stock of the Toronto-based company is trading near its 52-week low.

Benzinga's Edge Stock Rankings show that GV is exhibiting a negative price trend across all time frames.

Photo Courtesy: Rneaw on Shutterstock.com

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.